Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2022

Filing Date
Filed February 14, 2023
Period End
December 31, 2022
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-K filed February 14, 2023. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. describes itself as one of the world's leading clinical contract research organizations (CROs) by revenue, solely focused on outsourced clinical development services for the biotechnology, pharmaceutical and medical device industries, with particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI) and Central Nervous System (CNS).

For 2022, net revenue rose 27.8% to $1,459,996 thousanda ($1.46 billion) from $1,142,377 thousand, and net income increased to $245,368 thousand from $181,848 thousand. Diluted EPS was $7.28 versus $4.81. Backlog grew 17.2% to $2,339.6 million at December 31, 2022, with net new business awards of $1,829.5 million, and approximately $1,200.0 million to $1,220.0 million of backlog is expected to convert to net revenue in 2023.

Balance sheet and cash flow shifted notably during the year. Cash and cash equivalents fell to $28.3 millionb from $461.3 million, largely because of $847.8 million in share repurchases, and short-term debt of $50.0 million was drawn under the revolving Credit Facility, which the filing says is expected to be amended or replaced before its March 31, 2023 expiration. Net cash provided by operating activities was $388.1 million.

Total shareholders' equity fell to $386.4 millionc from $952.9 million, with an accumulated deficit of $359.8 million, reflecting the repurchases. The company had approximately 5,200 employees across 40 countries. The filing highlights several risks for investors: contracts are largely terminable on 30 days' notice, the backlog may not convert at historical rates, most Phase I–IV contracts are fixed-fee, and the Chief Executive Officer and founder, August J.

Troendle, controls approximately 23.4%d of outstanding shares. Deloitte & Touche LLP issued an unqualified opinion, and management concluded internal control over financial reporting was effective as of December 31, 2022.

Key Highlights

  1. Net revenue of $1,459,996 thousand for 2022, up 27.8% from $1,142,377 thousand in 2021
  2. Net income of $245,368 thousand, up from $181,848 thousand; diluted EPS of $7.28 versus $4.81
  3. Backlog increased 17.2% to $2,339.6 million at December 31, 2022; approximately $1,200.0–$1,220.0 million expected to convert to revenue in 2023
  4. Net new business awards of $1,829.5 million in 2022, compared with $1,610.4 million in 2021
  5. Share repurchases of $847.8 million in 2022 reduced cash to $28.3 million from $461.3 million and total shareholders' equity to $386.4 million
  6. Short-term debt of $50.0 million outstanding under the $250.0 million revolving Credit Facility, which expires March 31, 2023 unless amended or replaced
  7. Operating cash flow of $388.1 million in 2022, up from $263.3 million in 2021

Financial Statements

FY2022 against FY2021

Line itemFY2022FY2021Change
Revenue$1.46B$1.14B+27.8%
SG&A Expenses$131.40M$108.42M+21.2%
Operating Expenses$1.18B$943.76M+25.2%
Operating Income$278.70M$198.62M+40.3%
Net Income$245.37M$181.85M+34.9%
EPS (Basic)$7.57$5.06+49.6%
EPS (Diluted)$7.28$4.81+51.4%
Shares Outstanding (Basic)32.39M35.86M−9.7%
Shares Outstanding (Diluted)33.67M37.70M−10.7%

Frequently Asked Questions

  1. How did Medpace's revenue and profitability change in 2022?

    Net revenue rose $317.6 million, or 27.8%, to $1,460.0 million, driven primarily by Oncology, Metabolic, Cardiology and Central Nervous System activity. Income from operations increased to $278.7 million from $198.6 million, and net income rose to $245.4 million from $181.8 million. The filing attributes the rise in total direct costs mainly to higher reimbursed out-of-pocket expenses and personnel costs.

  2. Why did cash fall sharply and what does the company plan to do with its capital?

    Cash and cash equivalents declared $28.3 million at year-end 2022, down from $461.3 million, mainly due to $847.8 million of share repurchases, partly offset by $388.1 million of operating cash flow and $324.2 million of Credit Facility proceeds. The company says its expected cash needs include operational growth, capital expenditures, credit facility repayments, share repurchases and selective bolt-on acquisitions, and it believes its liquidity will be sufficient for the next 12 months.

  3. How concentrated is the customer base and what are the main contract risks?

    No single customer represented 10% or more of 2022 net revenue, but about one-fourth of net revenue came from the top ten customers. In 2022, 78% of net revenue came from small biopharmaceutical companies and 16% from mid-sized companies. Most customer contracts can be terminated without cause on 30 days' notice, and backlog is generally terminable, so the company does not believe backlog is necessarily a meaningful predictor of future results.

  4. Who controls the company and what governance concentration exists?

    Chief Executive Officer and founder August J. Troendle directly owns 806,643 shares and beneficially owns 6,483,019 shares held by Medpace Investors LLC, which together the filing states represent approximately 23.4% of outstanding common stock. The filing notes he can exert significant influence over director elections, charter amendments and major transactions, and that the company engages in related person transactions with entities he controls or has interests in.